- Home
- PRQR
as 07-26-2024 4:00pm EST
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
| Founded: | 2012 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 153.5M | IPO Year: | 2014 |
| Target Price: | $3.38 | AVG Volume (30 days): | 83.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.11 - $3.29 | Next Earning Date: | 08-05-2024 |
| Revenue: | $14,660,870 | Revenue Growth: | 252.63% |
| Revenue Growth (this year): | 135.93% | Revenue Growth (next year): | -3.34% |
Latest ProQR Therapeutics N.V. News
PRQR Breaking Stock News: Dive into PRQR Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Institutions own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) shares but retail investors control 46% of the company
GlobeNewswire
a month ago
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
AFP
2 months ago
Italy beat Bosnia in final Euros warm-up
AFP
2 months ago
Trump loyalists proud to support 'felon' at Las Vegas rally
Business Insider
2 months ago
US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
Insider Monkey
2 months ago
The Best Woody Perfume For Women
Compare PRQR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRQR ProQR Therapeutics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.